PMID: 16618011Apr 19, 2006Paper

Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial

Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
Trino BaptistaLuis Hernández

Abstract

To assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine. Forty patients taking olanzapine (10 mg daily) were randomly allocated to a metformin (n = 20; 850 to 1700 mg daily) or placebo (n = 20) group in a 14-week double-blind study. Waist circumference (WC), BWG, body mass index (BMI) fasting glucose, insulin, and lipids were evaluated at baseline and at Weeks 7 and 14 of treatment. At Week 14, BWG (kg) was similar in the metformin group (5.5 kg) and the placebo group (6.3 kg), P = 0.4. There were no differences between the changes in BMI, WC, glucose, insulin, insulin resistance index (HOMA-IR), and plasma lipid levels observed in the treatment group and the placebo group; however, glucose levels decreased significantly after metformin administration (P = 0.02). The HOMA-IR decreased significantly in both groups, but 3 subjects from the placebo group developed fasting glucose levels greater than 5 mmol/L. After taking metformin, triglyceride levels increased, but the cholesterol profile improved significantly. Metformin did not prevent olanzapine-induced BWG. While some lipid parameters worsened during placebo, the HOMA-IR improved in ...Continue Reading

Associated Clinical Trials

References

Sep 20, 2001·The Journal of Clinical Psychiatry·T BaptistaS de Mendoza
Apr 2, 2002·The American Journal of Psychiatry·John A MorrisonBruce A Barton
May 3, 2005·The American Journal of Psychiatry·David C HendersonDonald C Goff
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Trino BaptistaMaritza Martinez

❮ Previous
Next ❯

Citations

Jul 26, 2008·Postgraduate Medicine·Leslie Citrome, Betty Vreeland
Jan 13, 2009·Acta Psychiatrica Scandinavica·J M Meyer, S M Stahl
Jun 22, 2010·Phytotherapy Research : PTR·Yueshan HuGareth E Davies
Apr 5, 2011·Clinical Schizophrenia & Related Psychoses·M Patricia BallRobert W Buchanan
Feb 11, 2012·Cell Stress & Chaperones·Zsuzsanna Literáti-NagyLászló Vígh
Sep 4, 2015·The Journal of Endocrinology·Gary RemingtonMargaret Hahn
Feb 4, 2016·Journal of Psychopharmacology·Nir BarakJoseph H Albeck
May 14, 2008·The Australian and New Zealand Journal of Psychiatry·Sanil Rege
Jun 13, 2009·Journal of Child and Adolescent Psychopharmacology·Lauren ShinJean A Frazier
Jun 30, 2012·Pathology Oncology Research : POR·Zsuzsanna Literati-NagyZoltán Szilvássy
Jul 1, 2010·Expert Review of Neurotherapeutics·Lawrence Maayan, Christoph U Correll
Nov 18, 2009·Issues in Mental Health Nursing·Audrey K HouselTami R Argo
Dec 12, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN WFSBP Task force on Treatment Guidelines for Schizophrenia
Jun 11, 2015·Drugs·Ulrike HostalekSteven Hildemann
Jan 27, 2007·The Cochrane Database of Systematic Reviews·G FaulknerG Remington
Aug 19, 2010·Current Opinion in Endocrinology, Diabetes, and Obesity·Pornpoj Pramyothin, Lalita Khaodhiar
Dec 21, 2010·Journal of Psychopharmacology·Mehrul HasnainW Victor R Vieweg
Jan 19, 2010·Journal of Psychopharmacology·Linda Björkhem-BergmanJonatan D Lindh
Dec 7, 2017·Frontiers in Neuroscience·Jiezhong ChenChao Deng
Aug 15, 2020·The American Journal of Psychiatry·Christoph U CorrellRené S Kahn
Jul 14, 2007·International Journal of Clinical Practice·A TschonerC F Ebenbichler
Mar 26, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lawrence MaayanChristoph U Correll
Jun 17, 2011·International Journal of Psychiatry in Medicine·Maria GibsonBrigid Sullivan
Aug 29, 2013·BioMed Research International·Fatemeh RanjbarAmineh Alizadeh
Feb 3, 2011·British Journal of Clinical Pharmacology·Samir Kumar PraharajVinod Kumar Sinha
Jul 29, 2010·Nordic Journal of Psychiatry·Dan GotheforsUNKNOWN Swedish Psychiatric Association
May 11, 2007·Journal of Child and Adolescent Psychopharmacology·Zinoviy A GutkovichNatalie Wieland
May 20, 2008·CNS Drugs·Trino BaptistaSerge Beaulieu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here